Adam Murphy, MD
Urology · Chicago, ILNPI 1952563157
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $21,833 of the $33,290 with a category attached, or 65.6%. Sanofi accounts for 97.8% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2022 at $28,257 and has fallen 99.1% since, to $257 in 2025. Among urology clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 27 payments — averaging $1232.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$33K
- Blue Earth Diagnostics$242
- Boston Scientific$142
- Olympus America Inc.$133
- Progenics Pharmaceuticals, Inc.$97
- Sumitomo Pharma America, Inc.$97
- plus $15 from 1 others
What the payments were for
- Consulting fees$8,02324%
- Speaking & faculty fees$21,83366%
- Travel & lodging$2,3667%
- Food & beverage$1,0683%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 20 | $32,565 |
| Blue Earth Diagnostics | 2 | $242 |
| Boston Scientific | 1 | $142 |
| Olympus America Inc. | 1 | $133 |
| Progenics Pharmaceuticals, Inc. | 1 | $97 |
| Sumitomo Pharma America, Inc. | 1 | $97 |
| ABC Home Medical Supply, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JEVTANA$8,023
- POSLUMA$186
- GENERAL ERECTILE DYSFUNCTION$142
- iTIND System$133
How this compares
$33,290 in reported general payments places this provider in the 90th percentile of 550 urology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 14 | $10,825 |
| Finasteride | 64 | $1,069 |
| Tamsulosin Hcl | 67 | $951 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 14 | $40 |
Paid to pharmacies, not to this prescriber.
Other urology in Chicago
- Gary SteinbergChicago$529K
- Simone CrivellaroChicago$526K
- Brian HelfandChicago$517K
- Ashley RossChicago$404K
- Amy KrambeckChicago$356K
- Kevin ZornChicago$274K
- Joshua MeeksChicago$248K
- Edward SchaefferChicago$209K
- Paul YonoverChicago$179K
- Omer RaheemChicago$148K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.